| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2025 - 30 Jun 2025 | 16 Jul 2025 | 62 | 27% | 51% | 22% | 7% |
| 01 Jul 2024 - 31 Dec 2024 | 29 Jan 2025 | 54 | 30% | 52% | 18% | 32% |
| 01 Jan 2024 - 30 Jun 2024 | 22 Jul 2024 | 64 | 32% | 40% | 28% | 50% |
| 01 Jul 2023 - 31 Dec 2023 | 01 Feb 2024 | 74 | 18% | 48% | 34% | 47% |
| 01 Jan 2023 - 30 Jun 2023 | 04 Aug 2023 | 61 | 26% | 44% | 30% | 46% |
| 01 Jan 2022 - 30 Jun 2022 | 29 Jul 2022 | 47 | 32% | 4% | 64% | 40% |
| 01 Jan 2021 - 30 Jun 2021 | 30 Jul 2021 | 68 | 13% | 47% | 40% | 65% |
| 01 Jul 2020 - 31 Dec 2020 | 25 Jan 2021 | 61 | 20% | 45% | 35% | 60% |
| 01 Jan 2020 - 30 Jun 2020 | 30 Jul 2020 | 72 | 19% | 33% | 48% | 67% |
| 01 Jan 2019 - 30 Jun 2019 | 25 Jul 2019 | 58 | 25% | 47% | 28% | 57% |
| 01 Jan 2018 - 30 Jun 2018 | 27 Jul 2018 | 51 | 19% | 55% | 26% | 75% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
Payment terms including any standard contractual length of time for payment of invoices and the maximum contractual payment period, any changes to standard terms, whether suppliers have been notified or consulted on these changes.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
N/A
Maximum contractual payment period agreed
60
Complaints or concerns on non-payment are initially received and dealt with by the company's Finance department. Where possible simple, straight forward issues, for example administrative errors, will be resolved without the need for further escalation. Disputes involving more complex issues such as non-performance, pricing discrepancies or breach of contractual terms will be referred to the company's Commercial or Operations teams to liaise with the supplier and resolve. If required, disputes will be escalated to the company's Leadership team and/or Legal department to negotiate and resolve the issues arising.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
CATALENT U.K. SWINDON ZYDIS LIMITED is a leading pharmaceutical company based in Swindon, United Kingdom. They specialize in the development and manufacturing of innovative drug delivery technologies, with a focus on their proprietary Zydis technology.
Their sustainability program is an integral part of the company's operations, with a commitment to reducing their environmental impact and promoting sustainable practices. They have implemented various initiatives such as energy-efficient manufacturing processes, waste reduction programs, and sustainable sourcing of raw materials.
CATALENT U.K. SWINDON ZYDIS LIMITED offers a range of products and services to their clients, including formulation development, clinical manufacturing, and commercial scale production of oral solid dose and biologic products. Their flagship product, Zydis, is a fast-dissolving oral dosage form that provides enhanced patient compliance and convenience.
The company is led by a team of experienced and dedicated individuals, including Mark Surber (President, Biologics & Specialty Delivery) and Simon Downing (Managing Director). They are committed to driving innovation and growth within the pharmaceutical industry.
For more information on CATALENT U.K. SWINDON ZYDIS LIMITED and their services, you can visit their website at www.catalent.com/uk/swindon-zydis or contact their registered office at 1 Alder Road, Blagrove, Swindon, SN5 8RU, United Kingdom.